The initiation and progression of cancer, traditionally seen as a genetic disease, is now realized to involve epigenetic abnormalities along with genetic alterations. Recent advancements in the rapidly evolving field of cancer epigenetics have shown that disruption of various epigenetic mechanisms includes non-coding RNAs, such as microRNAs, DNA methylation, histone modifications, and nucleosome positioning are central to switching normal cells to malignant cells.

Thermo Fisher Scientific has developed powerful epigenetic research technologies spanning renewable antibody development, sample preparation, sequencing, quantitative PCR, & functional analysis assays to help unlock the mysteries of the cancer cell.

Renewable epigenetic antibodies

Epigenetic regulatory proteins are involved in a wide variety of chronic diseases, such as cancer, and are the target of an explosive new field of drug discovery. The ability to properly study most epigenetic changes, which determine which genes are “turned off and on,” are determined by the effectiveness of one critical tool—antibodies. Thermo Fisher Scientific has partnered with the Structural Genomics Consortium (SGC) to develop high-quality recombinant antibodies to read, write, and erase the epigenetic code.

View all epigenetic antibodies

Noncoding RNA


Chromatin Analysis


Read, write, & erase the epigenetic code through dynamic protein-DNA complexes

Map proteins across the genome

Understand chromatin structure

Investigate enzymes & substrate modifications

Profile chromatin enzymes or substrates

DNA Methylation


Analyze DNA methylation because not all genes are active all the time

Identify and Quantitate Methylated DNA

Fractionate CpG Methylation Density

For Research Use Only. Not for use in diagnostic procedures.